Home
Live Updates
Thubrikar Aortic Valve, Inc.: Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV at EuroPCR 2023 : comparemela.com
Thubrikar Aortic Valve, Inc.: Thubrikar Aortic Valve to Present Promising Initial Results of CE Mark-Enabling Study With Novel Optimum TAV at EuroPCR 2023
Thubrikar Aortic Valve, Inc., is happy to announce that results of the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV) in patients with severe aortic stenosis
Related Keywords
Philadelphia ,
Pennsylvania ,
United States ,
France ,
South Dakota ,
Paris ,
France General ,
New York ,
Brazil ,
Poland ,
Samir Wadke ,
Mano Thubrikar ,
Susheel Kodali ,
Mathew Williams ,
Jaroslaw Trebacz ,
Business Development ,
Heineman Medical Research Center ,
Advisors For The Company ,
Thubrikar Aortic Valve Inc ,
Langone Health ,
University Of Virginia ,
Heart Valve Center ,
Research Scientist At Edwards Lifesciences ,
Company Precision ,
Company Founder ,
Surgical Research ,
Presbyterian Columbia University Medical Center ,
Dakota School Of Mines ,
Structural Heart Valve Center At New York ,
Thubrikar Aortic Valve ,
Optimum Transcatheter Aortic Valve ,
Principal Investigator ,
Specialty Hospital Jana Pawla ,
Late Breaking Trials ,
Structural Heart Valve Center ,
Columbia University Medical Center ,
Medical Advisors ,
Aortic Valve ,
Biomedical Engineering ,
Distinguished Research Scientist ,
Edwards Lifesciences ,
South Dakota School ,
Vice President ,
Thubrikar ,
Aortic ,
Valve ,
Present ,
Romising ,
Nitial ,
Results ,
Park ,
Nabling ,
Study ,
Ith ,
Novel ,
Optimum ,
Uropcr ,
023 ,
comparemela.com © 2020. All Rights Reserved.